Clinical Trials Logo

Glaucoma clinical trials

View clinical trials related to Glaucoma.

Filter by:

NCT ID: NCT05269680 Recruiting - Open Angle Glaucoma Clinical Trials

STAR-LIFE: a Post-market Registry on MINIject

STAR-LIFE
Start date: July 20, 2022
Phase:
Study type: Observational

As part of the post-market clinical follow-up (PMCF), this registry is developed to ensure real-world data collection on MINIject device.

NCT ID: NCT05264818 Recruiting - Glaucoma Clinical Trials

Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma

GLAUCALYX
Start date: May 6, 2022
Phase:
Study type: Observational

The glycocalyx is a fibrillary lining structure that covers the inner surface of blood vessels. Composed of glycoproteins and polysaccharides, it is an essential determinant of vascular endothelial physiology: it limits coagulation activation and adapts capillary perfusion. Studies have shown glycocalyx alteration in various vascular and autoimmune pathologies such as diabetes, high blood pressure, chronic renal failure, ischemic heart disease, stroke, dementia, septic shock, and several other inflammatory pathologies with a common basis in vascular insufficiency. Glaucoma is a progressive, chronic and asymptomatic optic neuropathy characterized by visual field damage and abnormalities of the optic nerve head. Two hypotheses have been proposed as a basis for this progressive damage: - the mechanical theory, which explains the papillary excavation by a compression of the optic nerve head under the effect of high intraocular pressure; and - the ischemic theory, explained by a circulatory insufficiency at the level of the blood capillaries of the retina and especially of the optic nerve head. This latter theory is related to several pathologies that have circulatory insufficiency as common underlying pathophysiology, and in which damage to the glycocalyx has been well studied. Glycocalyx damage has rarely been studied in glaucoma. Yang et al. showed that the glycocalyx, present in Schlem's canal, plays a major role in the transduction of shear stress and regulation of outflow resistance to the aqueous humor, which may constitute an interesting biomarker for glaucomatous pathologies.

NCT ID: NCT05251792 Recruiting - Glaucoma Clinical Trials

Macular Pigment Optical Density in Primary Angle-closure Disease

Start date: November 11, 2021
Phase:
Study type: Observational

Glaucoma is the leading cause of irreversible blindness in the world, and primary angle-closure glaucoma (PACG) is the most important type of glaucoma in Asia. Primary angle closure disease (PACD) is a group of diseases related to PACG, and the pathogenesis is still unclear. Macular pigment has the functions of filtering short-wavelength waves and anti-oxidation, which are related to visual function. Previous studies have found that the macular pigment density (MPOD) is significantly reduced in primary open-angle glaucoma. This project uses the single-wavelength reflection method to measure MPOD, observes the characteristics of PACD and the normal control group's changes in retinal MPOD, and explains the relationship between PACD's MPOD changes and angle-closure glaucoma optic nerve damage

NCT ID: NCT05241938 Recruiting - Ocular Hypertension Clinical Trials

PSLT Compared to Prostaglandin Analogue Eye Drops

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

This study aims to compare the efficacy of PSLT and the topical use of prostaglandin-like hypotensive eye drops in the treatment of ocular hypertensive or glaucomatous patients in decreasing intraocular pressure and measuring changes in functional, structural and biomechanical parameters evaluated by computerized perimetry and optical coherence tomography (OCT) related to pressure change resulting from treatments

NCT ID: NCT05235321 Recruiting - Glaucoma Clinical Trials

Automated Applanation Tonometry

Start date: November 21, 2022
Phase: N/A
Study type: Interventional

Goldmann Applanation Tonometry (GAT) is considered the clinical gold standard for eye pressure measurements and yet it is known to be a subjective measurement with limited repeatability and limited portability. The purpose of this study is to develop an automated and objective method for performing applanation tonometry using standard ophthalmic equipment as well as using 2 portable prototypes.

NCT ID: NCT05232539 Recruiting - Glaucoma Clinical Trials

Efficiency of Intraoperative Optical Coherence Tomography (iOCT)

Start date: May 2022
Phase: N/A
Study type: Interventional

Efficiency of Intraoperative Optical Coherence Tomography (iOCT) Hypothesis: The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps (incision adaptation, differentiation of healthy and pathological tissue, placement of the implant, graft, etc.) The disadvantage is the prolongation of the operation and thus the theoretical increase in possible complications related to the operation (bleeding, infection, patient subjective problems - pain, restlessness, poorer cooperation and the resulting other possible risks, such as unexpected patient movement). Aim: Determining the effectiveness of iOCT use in different types of eye surgery. Evaluation of advantages and disadvantages of using iOCT.

NCT ID: NCT05206877 Recruiting - Glaucoma Clinical Trials

Topical Insulin for Glaucoma

TING1
Start date: April 1, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

NCT ID: NCT05180994 Recruiting - Clinical trials for Glaucoma Following Surgery

Topical Infliximab in Eyes With Penetrating Keratoplasty

Start date: May 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

NCT ID: NCT05163951 Recruiting - Clinical trials for Primary Angle Closure Glaucoma

Trabeculectomy Versus Peripheral Iridectomy Plus Goniotomy in Advanced PACG

TVG
Start date: January 5, 2022
Phase: N/A
Study type: Interventional

A multicenter, parallel, open, non-inferior randomized controlled trial is conducted to compare the effectiveness and safety of trabeculectomy and peripheral iridectomy plus goniotomy (TVG) in the treatment of advanced primary angle closure glaucoma with no or mild cataracts.

NCT ID: NCT05163093 Recruiting - Clinical trials for Angle-Closure Glaucoma

Research on the Diagnosis and Treatment of Angle Closure Glaucoma With Abnormal Lens Zonular

Start date: November 1, 2020
Phase:
Study type: Observational

Angle-closure glaucoma is the main type of glaucoma in China, which is divided into acute and chronic angle-closure glaucoma. Previous studies from our group have found that, in lens excision combined with glaucoma surgery, accounted for 46.2% of patients were ligament abnormalities, such as lens subluxation with suspensory ligament relaxation. And it was more common in acute angle-closure glaucoma (55.8%). In acute angle-closure glaucoma, approximately 55.2% of suspensory ligament abnormalities were not diagnosed preoperatively depend on UBM and slit lamp examinations. The purpose of this study was to find a better preoperative diagnosis method of the suspensory ligament abnormality, and to observe the influence of the suspensory ligament abnormality on the occurrence, development and treatment effect of acute angle-closure glaucoma. We plan to collect patients with acute angle-closure glaucoma with monocular onset and exclude traumatic, secondary glaucoma and a history of intraocular surgery. The onset eyes were treated with combined operation, and divided into two groups according to the presence or absence of suspensory ligament abnormalities. The fellow eyes were treated with laser peripheral iridectomy, and followed examination, including UBM, anterior-segment OCT, and IOL master 700, before and after bow excitation test. Then follow up patients every six months. Ultimately, the fellow eyes will be treated with combined surgery after 2.5 years or the fellow eyes occur acute angle-closure glaucoma. In the end, we evaluate the sensitivity and specificity of each index, and the influence of suspensory ligament abnormality on angle-closure glaucoma progression.